Emmanuel Bachy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8471259/publications.pdf

Version: 2024-02-01

143
papers
citations
147801
31
57
ph-index
151
151
151
151
15444

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Advances, 2023, 7, 744-755.	5.2	5
2	Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 975-984.	2.5	12
3	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas. American Journal of Surgical Pathology, 2022, 46, 58-70.	3.7	12
4	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia and Lymphoma, 2022, 63, 599-607.	1.3	0
5	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood, 2022, 139, 1541-1556.	1.4	23
6	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). Journal of Clinical Oncology, 2022, 40, 242-251.	1.6	90
7	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers, 2022, 14, 660.	3.7	3
8	The upper ECHELON against T-cell lymphoma. Annals of Oncology, 2022, 33, 239-241.	1.2	0
9	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood, 2022, 139, 2338-2346.	1.4	18
10	Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study Journal of Clinical Oncology, 2022, 40, 7552-7552.	1.6	3
11	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Advances, 2021, 5, 539-548.	5.2	38
12	Realâ€life targeted nextâ€generation sequencing for lymphoma diagnosis over 1Âyear from the French Lymphoma Network. British Journal of Haematology, 2021, 193, 1110-1122.	2.5	8
13	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. Blood Advances, 2021, 5, 1729-1732.	5.2	6
14	Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 2118-2124.	2.4	6
15	Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. Advances in Therapy, 2021, 38, 3489-3505.	2.9	2
16	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/ <scp>Tâ€Cell</scp> lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (<scp>SFGMâ€TC</scp>). American Journal of Hematology, 2021, 96, 834-845.	4.1	5
17	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematology,the, 2021, 8, e355-e364.	4.6	43
18	CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160

#	Article	IF	Citations
19	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. Journal of Translational Medicine, 2021, 19, 265.	4.4	20
20	Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. Clinical Nuclear Medicine, 2021, 46, 627-634.	1.3	25
21	Adverse outcome in follicular lymphoma is associated with <i>MYC</i> rearrangements but not <i>MYC</i> extra copies. British Journal of Haematology, 2021, 194, 382-392.	2.5	5
22	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. Transplantation, 2021, 105, 1858-1868.	1.0	3
23	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. Journal of Clinical Investigation, 2021, 131, .	8.2	4
24	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	1.8	12
25	Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Advances, 2021, 5, 3227-3239.	5.2	28
26	New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas. Current Oncology, 2021, 28, 3430-3447.	2.2	8
27	Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S243.	0.4	O
28	Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S245.	0.4	0
29	IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S403-S404.	0.4	O
30	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia, 2021, 35, 3585-3588.	7.2	72
31	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood, 2021, 138, 128-128.	1.4	13
32	Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. Blood, 2021, 138, 130-130.	1.4	23
33	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. Blood, 2021, 138, 885-885.	1.4	5
34	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. Blood, 2021, 138, 131-131.	1.4	8
35	Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy. Blood. 2021. 138. 1387-1387.	1.4	O
36	Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group. Blood, 2021, 138, 743-743.	1.4	9

#	Article	IF	Citations
37	Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 2021, 138, 93-93.	1.4	12
38	A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry. Blood, 2021, 138, 92-92.	1.4	7
39	Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. Blood, 2021, 138, 2417-2417.	1.4	3
40	Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. Blood, 2021, 138, 3574-3574.	1.4	5
41	Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study. Blood, 2021, 138, 129-129.	1.4	21
42	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas. Blood, 2021, 138, 809-809.	1.4	1
43	CAR-T cells, from principle to clinical applications. Bulletin Du Cancer, 2021, 108, S4-S17.	1.6	15
44	CAR-T cell: Toxicities issues: Mechanisms and clinical management. Bulletin Du Cancer, 2021, 108, S117-S127.	1.6	7
45	Reply to S. Fuji. Journal of Clinical Oncology, 2020, 38, 523-523.	1.6	1
46	Controversies in the Treatment of Peripheral Tâ€cell Lymphoma. HemaSphere, 2020, 4, e461.	2.7	5
47	Commercial <scp>antiâ€CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. American Journal of Hematology, 2020, 95, 1324-1333.	4.1	89
48	Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Scientific Reports, 2020, 10, 18997.	3.3	59
49	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematological Oncology, 2020, 38, 137-145.	1.7	3
50	Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). Bone Marrow Transplantation, 2020, 55, 2052-2055.	2.4	5
51	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood, 2019, 134, 1132-1143.	1.4	81
52	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. Journal of Clinical Oncology, 2019, 37, 2815-2824.	1.6	173
53	Earlyâ€onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. American Journal of Hematology, 2019, 94, E109-E111.	4.1	9
54	Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. Journal of Antimicrobial Chemotherapy, 2019, 74, 2676-2680.	3.0	4

#	Article	IF	CITATIONS
55	Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. Journal of Oncology Practice, 2019, 15, 147-148.	2.5	0
56	Breast implant-associated anaplastic large cell lymphoma. Blood Research, 2019, 54, 3-3.	1.3	2
57	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. Journal of Clinical Oncology, 2019, 37, 144-152.	1.6	142
58	ONE-YEAR REAL-LIFE TARGETED NEXT GENERATION SEQUENCING FOR LYMPHOMA DIAGNOSIS: STUDY OF PATIENTS FROM THE FRENCH LYMPHOMA NETWORK IN RHÔNE-ALPES. Hematological Oncology, 2019, 37, 186-186.	1.7	0
59	PD-1 BLOCKADE IN A FRENCH SERIES OF 13 RELAPSED / REFRACTORY NK/T-CELL LYMPHOMA PATIENTS. Hematological Oncology, 2019, 37, 272-273.	1.7	1
60	Single-agent ibrutinib in RESONATE-2â,,¢ and RESONATEâ,,¢ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Annals of Hematology, 2019, 98, 2749-2760.	1.8	9
61	S1600 REALâ€WORLD RESULTS ON CD19 CAR Tâ€CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTOR' DIFFUSE LARGE Bâ€CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM. HemaSphere, 2019, 3, 736-737.		1
62	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. Blood, 2019, 134, 1524-1524.	1.4	3
63	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data. Blood, 2019, 134, 4021-4021.	1.4	0
64	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. Blood, 2019, 134, 3781-3781.	1.4	0
65	Interpreting results in clinical trials and subgroup analyzes. Hematologie, 2019, 25, 3-10.	0.0	0
66	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood, 2018, 132, 49-58.	1.4	130
67	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Annals of Oncology, 2018, 29, 715-723.	1.2	110
68	Refractory diffuse large Bâ€cell lymphoma after firstâ€line immuno T: Treatment options and outcomes. Hematological Oncology, 2018, 36, 533-542.	1.7	5
69	From hepatitis C virus infection to B-cell lymphoma. Annals of Oncology, 2018, 29, 92-100.	1.2	63
70	Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?. Hematological Oncology, 2018, 36, 399-406.	1.7	25
71	SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Annals of Hematology, 2018, 97, 123-131.	1.8	12
72	Chronic Borrelia burgdorferi infection triggers NKT lymphomagenesis. Blood, 2018, 132, 2691-2695.	1.4	4

#	Article	IF	CITATIONS
73	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Transplantation, 2018, 102, 1914-1923.	1.0	11
74	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. Cancer Cell, 2018, 34, 286-297.e10.	16.8	88
75	Highâ€dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the <scp>EBMT</scp> Lymphoma Working Party and <scp>FIL</scp> â€ <scp>GITMO</scp> . British Journal of Haematology, 2018, 182, 807-815.	2.5	19
76	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391.	27.8	276
77	Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression. Frontiers in Immunology, 2018, 9, 3178.	4.8	16
78	Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study. Blood, 2018, 132, 999-999.	1.4	8
79	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	1.4	0
80	Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR). Blood, 2018, 132, 2266-2266.	1.4	0
81	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data. Blood, 2018, 132, 1641-1641.	1.4	0
82	Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation. Blood, 2018, 132, 5351-5351.	1.4	1
83	Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University. Blood, 2018, 132, 4215-4215.	1.4	0
84	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2017, 52, 1120-1125.	2.4	8
85	FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood, 2017, 130, 1315-1326.	1.4	87
86	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in theÂpre-brentuximab vedotin era: A LYSA/SFGM-TC study. European Journal of Cancer, 2017, 83, 146-153.	2.8	18
87	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clinical Infectious Diseases, 2017, 65, 1819-1828.	5.8	179
88	CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS. Hematological Oncology, 2017, 35, 34-35.	1.7	1
89	ROLE OF UPâ€FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL Tâ€CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS. Hematological Oncology, 2017, 35, 76-77.	1.7	0
90	INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY. Hematological Oncology, 2017, 35, 165-167.	1.7	0

#	Article	IF	CITATIONS
91	CHARACTERISTICS AND OUTCOMES OF RELAPSED FOLLICULAR LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA. Hematological Oncology, 2017, 35, 220-221.	1.7	0
92	Arrayâ€CGH predicts prognosis in plasma cell postâ€transplantation lymphoproliferative disorders. Genes Chromosomes and Cancer, 2017, 56, 221-230.	2.8	10
93	Comparative toxicities of 3 platinumâ€containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematological Oncology, 2017, 35, 584-590.	1.7	28
94	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplantation, 2017, 52, 216-221.	2.4	102
95	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 2016, 7, 85573-85583.	1.8	13
96	Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo. European Journal of Cell Biology, 2016, 95, 331-341.	3.6	9
97	<scp>S</scp> tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: <scp>A</scp> n exploratory analysis of the PRIMA cohort study. American Journal of Hematology, 2016, 91, 410-415.	4.1	5
98	Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica, 2016, 101, e103-e106.	3.5	30
99	A matched case–control study of toxoplasmosis after allogeneic haematopoieticÂstem cell transplantation: still a devastating complication. Clinical Microbiology and Infection, 2016, 22, 636-641.	6.0	35
100	CD1d-restricted peripheral T cell lymphoma in mice and humans. Journal of Experimental Medicine, 2016, 213, 841-857.	8.5	19
101	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplantation, 2016, 51, 1184-1190.	2.4	31
102	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	4.1	180
103	Molecular Classification of Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1163-1177.	2.2	22
104	Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis. Transplant Infectious Disease, 2016, 18, 595-600.	1.7	6
105	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2016, 51, 365-371.	2.4	43
106	HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns. Journal of Infection, 2016, 72, 214-222.	3.3	32
107	Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATETM and RESONATE-2TM with the French Lyon-Sud Database. Blood, 2016, 128, 2039-2039.	1.4	0
108	Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. Haematologica, 2015, 100, 1579-1586.	3.5	28

#	Article	IF	CITATIONS
109	Chemotherapy-free treatment in patients with follicular lymphoma. Expert Review of Hematology, 2015, 8, 187-203.	2.2	8
110	Sarcoidosis and lymphoma: a comparative study. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 871-878.	0.5	25
111	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investigational New Drugs, 2015, 33, 423-431.	2.6	33
112	Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?. Lancet Haematology,the, 2015, 2, e307-e308.	4.6	2
113	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 107-118.	3.4	16
114	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase $1b/2$ study. Lancet Haematology,the, 2015, 2, e160-e165.	4.6	95
115	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). Cancer Chemotherapy and Pharmacology, 2015, 76, 939-948.	2.3	7
116	Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study. Blood, 2015, 126, 1505-1505.	1.4	0
117	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney International, 2014, 85, 182-190.	5.2	35
118	Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncology, The, 2014, 15, 7-8.	10.7	36
119	ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of Oncology, 2014, 25, 1622-1628.	1.2	91
120	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. Clinical Cancer Research, 2014, 20, 5226-5239.	7.0	17
121	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. Human Pathology, 2014, 45, 2085-2093.	2.0	23
122	Time has come for immunotherapy in PTCL. Blood, 2014, 123, 3059-3060.	1.4	5
123	A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients. Blood, 2014, 124, 1721-1721.	1.4	0
124	Identification of Previously Unrecognized CD1d-Restricted Peripheral T Cell Lymphomas (PTCLs) in Mouse and Human Reveals Blocking Anti-CD1d Monoclonal Antibodies As a New Therapeutic Possibility in PTCLs. Blood, 2014, 124, 4485-4485.	1.4	0
125	Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 41-45.	1.3	26
126	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica, 2013, 98, 1107-1114.	3.5	70

#	Article	IF	Citations
127	Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, <i><scp>IGHV</scp></i> mutations, and survival. A study of 76 cases. Histopathology, 2013, 62, 876-893.	2.9	12
128	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica, 2013, 98, 776-783.	3.5	38
129	Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood, 2012, 120, 2144-2154.	1.4	102
130	What Is the Best First-Line Treatment Strategy for Patients with Indolent Lymphomas?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 488-493.	3.8	3
131	P53 Prevents TCR-Dependent Peripheral T-Cell Lymphomagenesis From Chronically Stimulated T Cells Blood, 2012, 120, 2401-2401.	1.4	0
132	Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study Blood, 2012, 120, 2649-2649.	1.4	0
133	Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. Best Practice and Research in Clinical Haematology, 2011, 24, 257-270.	1.7	11
134	Quantitative and functional analyses of CD4 ⁺ CD25 ⁺ FoxP3 ⁺ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. British Journal of Haematology, 2011, 153, 139-143.	2.5	17
135	Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 2010, 28, 822-829.	1.6	63
136	Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program Blood, 2010, 116, 1794-1794.	1.4	3
137	Hepatitis C virus infection and lymphoma. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010004.	1.3	18
138	Hodgkin Variant of Richter's Syndrome: Report of 34 Cases. A Role of EBV in Transformation Blood, 2009, 114, 1550-1550.	1.4	0
139	Impact of Donor-Derived Invariant Natural Killer T (iNKT) Cell Reconstitution After Allogeneic Haematopoietic Stem Cell Transplantation Blood, 2009, 114, 346-346.	1.4	30
140	Long Term Follow-up of the GELF86 French and Belgian Trials: Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission. Blood, 2008, 112, 2590-2590.	1.4	5
141	Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica, 2007, 92, 1238-1241.	3.5	58
142	The Proportion of Natural Regulatory T-Cells CD4+CD25+Foxp3+ in Chronic Phase Chronic Myelogenous Leukemia Patients Correlates with Sokal Score at Diagnosis and Is Increased during Imatinib Mesylate Treatment Blood, 2007, 110, 2933-2933.	1.4	0
143	Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation Blood, 2006, 108, 2190-2190.	1.4	8